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Abstract 
In freshly prepared low density lipoprotein (LDL), ascorbate inhibited LDL oxidation by macrophages at the higher concentrations tested (6&100 
uM). In contrast. with LDL that had been allowed to autoxidise in the refrigerator (3°C) for at least 10 weeks after isolation (mildlv oxidised or 
‘mi&nally-mod&d LDL), ascorbate did not inhibit the moditIcation of LDL in-the preset& of macrophages. Ascorbate actually modified autoxidised 
LDL itself in the absence of macrophages to greatly increase its uptake by macrophages. The modification of autoxidised LDL by ascorbate increased 
the levels of thiobarbituric acid-reactive substances in the medium and was completely inhibited by the antioxidant butylated hydroxytoluene. Thus 
the effects of ascorbate on unoxidized LDL can be very different to those on mildly oxidised LDL. 
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1. Introduction 
It has been well documented that low density lipopro- 
tein (LDL) plays an important role in atherosclerosis, the 
underlying cause of coronary heart disease and strokes. 
Oxidatively modified LDL is taken up by macrophages 
at a much greater rate than native LDL, via ‘scavenger’ 
receptors [1,2] leading to the formation of cholesterol- 
laden ‘foam cells’ [3]. Foam cells are characteristic of 
many early and late atherosclerotic lesions. The role of 
antioxidants as a defence against lipid peroxidation has 
thus been considered as potentially important in the pro- 
tection against atherosclerosis. 
Ascorbic acid (vitamin C) is a major water-soluble 
antioxidant in plasma. It has been shown to inhibit LDL 
oxidation by a water-soluble azoinitiator, activated neu- 
trophils or cigarette smoke [4], and by metal ions and 
cells [5,6,7]. Physiological concentrations of ascorbate 
inhibit LDL oxidation by human monocyte-derived 
macrophages or copper ions and help to preserve its 
endogenous lipid-soluble antioxidants [5,6]. Ascorbate 
increases the lag phase before LDL is oxidised by copper 
ions [8]. 
Ascorbate has been reported to regenerate the anti- 
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Abbreviations: BHT, butylated hydroxytoluene; DMEM, Dulbecco’s 
modified Eagle’s medium; FCS, foetal calf serum; LDL, low density 
lipoprotein; MDA, malondialdehyde; TBARS, thiobarbituric acid- 
reactive substances. 
oxidants probucol [9] and a-tocopherol [lo] from their 
radicals in oxidising LDL particles, and to decrease the 
in vivo oxidation of LDL in genetically scorbutic rats 
[l 11. Retsky et al. [7] have suggested two mechanisms by 
which ascorbate may protect LDL against oxidation; 
ascorbic acid may scavenge free radicals in the aqueous 
phase or dehydro+ascorbic acid (the oxidation product 
of ascorbic acid), or its decomposition products, may 
modify LDL leading to decreased copper binding to the 
LDL particle and increased resistance to copper-depend- 
ent oxidation. 
Ascorbate can inhibit atherosclerosis in cholesterol- 
fed rabbits even when the plasma cholesterol evels are 
not decreased by it [12,13]. Another study has demon- 
strated an inverse relationship between ascorbate levels 
in human plasma and the occurrence of coronary heart 
disease (although low levels of vitamin E were a stronger 
risk factor) [14,15] and stroke [14]. The risk of angina is 
inversely related to the plasma ascorbate level, but this 
is partly due to the low plasma ascorbate levels found in 
smokers [ 161. The mortality from cardiovascular disease 
and all causes has been reported by Enstrom et al. to be 
strongly inversely related to ascorbate intake in males 
and more weakly in females [17]. Contrary to these re- 
sults, two studies on antioxidant vitamin intake [l&19] 
showed no apparent effect of ascorbate on coronary 
heart disease. 
Ascorbate can act as a prooxidant as well as an antiox- 
idant [20,21]. We report here that ascorbate can either 
increase or decrease the modification of LDL by macro- 
phages depending upon the age of the LDL preparation. 
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2. Materials and methods 15 min. The absorbance was read at 535 nm. Standards were prepared 
using tetramethoxypropane. 
2.1. Materials 
Dulbecco’s modified Eagle’s medium (DMEM), foetal calf serum 
(FCS), gentamicin (10 mg/ml), penicillinlstreptomicin (5,000 i.u./5,000 
pg per ml), amphotericin B (250 &ml) and glutamine (200 mM) were 
purchased from Gibco, Uxbridge, Middlx., UK. Ham’s F-10 medium 
was from ICN Flow, High Wycombe, Bucks, UK. Ferrous sulphate, 
Phenol red solution (0.5% w/v), L-ascorbic acid (sodium salt) and tetra- 
methoxypropane were from Sigma Chemical Co., Poole, Dorset, UK. 
Falcon multiwell tissue culture plates (18 mm and 22 mm diameter 
wells) were from Fahrenheit, Bradwell Abbey, Milton Keynes, Bucks., 
UK and female Swiss T.O. mice were purchased from Tuck and Son, 
Battlesbridge, Essex, UK. 
2.2. Isolation and radioiodination of LDL 
LDL (1.019-l .063 g/ml) was isolated from blood donated by healthy 
volunteers by sequential density ultracentrifugation as previously de- 
scribed [22], and radiolabelled with Na’*‘I using iodine monochloride 
[23]. The ‘251-labelled LDL was mixed with nonlabelled LDL to give a 
specific activity of 20-40 cpm/ng and diluted to 2 mg protein/ml with 
buffer containing 100 ,uM EDTA for storage at 3°C. When used at 100 
pg protein/ml, this would give a final EDTA concentration of 5 PM. 
This standardisation of the EDTA concentration was considered im- 
portant as EDTA can either stimulate or inhibit LDL oxidation by cells 
depending on its concentration [24]. 
2.3. Modljication of LDL by cells 
Resident peritoneal macrophages were isolated from female Swiss 
T.O. mice by peritoneal lavage [25]. The peritoneal cells were plated at 
0.75 x lo6 cells per 18 mm well, and used for the modification of LDL. 
‘251-labelled LDL (100 pug protein/ml) was incubated with macrophages 
(macrophage-modified LDL) or in cell-free wells (control LDL) at 
37”C, under 5% CO2 for 16 or 18 h in 0.4 ml of Ham’s F-10 medium 
supplemented with FeSO, (6 PM final) [26], Phenol red (12 &ml) and 
gentamicin (50 &ml), with varying concentrations of ascorbate. For 
experiments in which a thiobarbituric acid-reactive substances 
(TBARS) assay was used, cells were plated at 1.5 x lo6 cells per well in 
22 mm diameter wells with 1 ml medium per well. After incubation, 
the modified medium was collected and centrifuged (MSE Micro- 
centaur, 13,000 rpm for 2.5 min) to remove any detached cells. 
2.4. Uptake of modified LDL by cells 
For measurement of uptake of modified LDL, mouse peritoneal 
macrophages (1.25 x lo6 cells per 22 mm diameter well) or mouse 5774 
macrophage-like cells (plated at 0.2 x lo6 cells per 22 mm diameter well 
and used the day after) were used (‘target’ macrophages). Macrophage- 
modified or control LDL was diluted to 10 ,ug protein/ml in DMEM 
containinn 10% (v/v) FCS. nenicillin/strentomicin (100 i.u./lOO fig per 
ml) and t&an&in’(50 &nl) for the peritoneal cells or in dhTgM 
containing 20% (v/v) heat-inactivated FCS, amphotericin B (1 &ml), 
L-glutamine (2 mM) and penicillinlstreptomicin (10 i.u./lO pug per ml) 
for the J774 cells (media in which cells cannot oxidise LDL [27]). The 
LDL was then incubated with the ‘target’ macrophages or cell-free wells 
(1 ml/well) for 22 h. 
The degradation of modified LDL was assessed by measuring the 
radioactive noniodide trichloroacetic acid-soluble degradation prod- 
ucts in the medium [22]. The degradation products in the cell-free wells 
were subtracted from the values for the macrophage wells. The cells 
were washed, lysed with 0.2 M NaOH, and the cell protein and cell- 
associated radioactivity measured [23]. Any radioactivity remaining in 
the cell-free wells was subtracted from the values for the macrophage 
wells. Since much radioactivity remains in the cells with oxidised LDL, 
the cell-associated values were added to the degradation values to 
obtain total LDL uptake [28]. 
2.5. Thiobarbituric acid-reactive substances assay 
The method used was modified from that described by Bemheim et 
al. [29]. Butylated hydroxytoluene (BHT) and EDTA at final concentra- 
tions of 20 PM and 1 mM, respectively, were added to 250 ~1 samples 
of modified or control LDL (100 pg protein/ml) to prevent further 
oxidation. 2 ml of 0.335% (w/v) thiobarbituric acid in 10% (w/v) trichlo- 
roacetic acid was added to e&h sample and incubated ‘at 45°C for 
3. Results 
The effect of ascorbate on the macrophage-mediated 
oxidation of LDL was studied by incubating mouse per- 
itoneal macrophages with 1251-labelled LDL in Ham’s 
F-10 medium containing various concentrations of as- 
corbate. A second set of macrophages (‘target’ macro- 
phages) was used to determine the rate of uptake of the 
LDL. In the absence of ascorbate, the macrophages oxi- 
dised the 1251-labelled LDL so that it was taken up much 
faster than the control LDL by the second set of macro- 
phages (Fig. 1A). As reported before [28], the oxidised 
12sI-labelled LDL was resistant o degradation and much 
of its radioactivity accumulated within the cells. 1251- 
labelled LDL uptake was therefore calculated by adding 
the degraded noniodide trichloroacetic acid-soluble radi- 
oactivity released into the medium to the cell-associated 
radioactivity. 
Ascorbate inhibited the modification of ‘fresh’ LDL 
by macrophages, with 80 ,uM giving a total or near total 
inhibition in the experiment shown in Fig. 1A. At lower 
concentrations, the ascorbate might have slightly in- 
creased the modification of LDL by macrophages, since 
greater modification of LDL was seen at 20 PM and 40 
,uM than occurred in the absence of ascorbate. This ef- 
fect, although slight, was observed in all experiments on 
‘fresh’ LDL (LDL used within 7 weeks of isolation). 
Control LDL (LDL incubated in cell-free wells) was 
taken up somewhat faster after incubation with about 40 
,uM ascorbate. Although the extent of modification was 
only low, this effect was observed in a number of exper- 
iments. 
The effects of ascorbate on the same batch of LDL 10 
weeks after the start of its isolation from blood are 
shown in Fig. 1B. With increasing concentrations of as- 
corbate there was an increase, rather than a decrease, in 
LDL modification by macrophages. There was also a 
great increase in the modification of the control LDL. 
About half of the ascorbate-modified LDL that was 
taken up by the macrophages over 22 h was not degraded 
by them (Fig. 1B) and so it appears that ascorbate-mod- 
ified LDL, like oxidised LDL [28], is resistant to lyso- 
somal degradation. The only difference between the two 
experiments (other than that they had, of course, to be 
carried out at different times) was the duration of storage 
of the isolated LDL. 
Fig. 2 demonstrates the different effects of ascorbate 
on ‘fresh’ and ‘aged’ LDL within the same experiment. 
Ascorbate inhibited LDL modification by macrophages 
when the LDL was ‘fresh’, with the exception of the 
lower doses. It did not inhibit the modification of LDL 
in the presence of macrophages, and modified the con- 
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trol LDL itself, however, when the ‘aged’ LDL was used. 
The ‘fresh’ LDL, whose oxidation by macrophages was 
inhibited by ascorbate when it was 5 weeks old (Fig. 2A), 
was not effectively protected by ascorbate from mod& 
cation in the presence of macrophages when it was 20 
weeks old and indeed ascorbate itself modified the ‘aged 
LDL in a dose-dependent manner in the absence of mac- 
rophages (Fig. 2B). 
The effects of ascorbate on ‘aged’ LDL were not due 
to any contaminating iron or copper ions in the ascor- 
bate solution as the levels of iron and copper in 100 ,uM 
ascorbate solution would have been less than 1 nM each, 
A. 
0 
0 20 40 50 60 50 100 native 
Concentration of ascorbate (AIM) 
60 80 100 native 
Concentration of amMate (rrM) 
Fig. 1. ‘zsI-labelled LDL (100 fig protein/ml) was incubated for 18 h in 
triplicate wells with mouse peritoneal macrophages (macrophage- 
modified LDL) or in cell-free wells (control LDL) in Ham’s F-10 me- 
dium and the indicated amount of ascorbic acid. The LDL was then 
diluted to 10 ,ug protein/ml in serum-containing DMEM and incubated 
with ‘target’ macrophages (mouse peritoneal macrophages in Fig. lA, 
J774 macrophages in Fig. 1B) or in cell-free wells for 22 h. The rates 
of degradation (lower area of bar) and cell association (upper area of 
bar) of the LDL were then measured. The total height of the histobar 
indicates the uptake (degradation plus cell-association) of the LDL. 
The uptake of native (non-incubated) LDL is also shown. (A) LDL 
batch A was used 7 weeks after starting its isolation from blood; (B) 
LDL batch A was used 10 weeks after starting the isolation. The 
mean ?r S.E.M. of triplicates are shown. 
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Concentratbn of 
30 
asorbate (uM) 
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Fig. 2. ‘Aged’ or ‘fresh’ lz5 I-labelled LDL (100 ,ug protein/ml) was 
incubated for 18 h in triplicate with macrophages or in cell-free wells 
in Ham’s F-10 medium and the indicated amounts of ascorbate. The 
LDL was then diluted to 10 pg protetiml with serumcontaining 
DMEM and incubated with ‘target’ J774 macrophages or in cell-free 
wells for 22 h. The rates of &gradation (lower area of bar) and cell- 
association (upper area of bar) of the LDL were then measured. (A) 
LDL batch B (5 weeks old; ‘fresh’) and LDL batch A (15 weeks old; 
‘aged’), tested in the same experiment; (B) LDL batch C (3 weeks old; 
‘fresh’) and LDL batch B (20 weeks old; ‘aged’), tested in the same 
experiment. The mean & S.E.M. of triplicates are shown. Note the 
different effects of ascorbate on ‘fresh’ and ‘aged’ batch B LDL. 
as determined by atomic absorption spectroscopy (in a 
100 mM solution of ascorbate). 
Fig. 3 shows that adding 100 ,uM ascorbate increased 
the modification of ‘aged’ LDL incubated both in the 
presence or absence of macrophages, as measured by 
macrophage uptake or TBARS. (Adding ascorbate di- 
rectly to the TBARS assay tubes did not increase the 
absorbance above the reagent blanks, either in the pres- 
ence or absence of LDL.) Adding the antioxidant BHT 
together with the ascorbate during the modification stage 
totally prevented the enhanced uptake of the LDL by the 
266 
LDL UPTAKE 
control ascorbate 
B. TBARS 
50 1 
El MacmphapbmDdmedLoL 
0 c4nbulLoL 
as.c~rbate + BHT 
control ascorbate ascorbate + BHT 
Fig. 3. ‘Aged’ lz5 I-labelled LDL (100 pg protein/ml; 29 weeks old) was 
incubated for 16 h in triplicate with macrophages or in cell-free wells 
in Ham’s F-10 medium without ascorbate, with 100 PM ascorbate or 
with 100 pM ascorbate plus 20 PM BHT. Samples were then assayed 
for TBARS (B) or the LDL was diluted to 10 pug protein/ml in serum- 
containing DMEM and incubated with ‘target’ 5774 macrophages or 
in cell-free wells for 22 h. The rates of degradation (lower area of bar) 
and cell-association (upper area of bar) were then measured (A). The 
mean f S.E.M. of triplicates are shown. These results were confirmed 
by another experiment. 
target macrophages and the increased formation of 
TBARS. 
4. Discussion 
Ascorbate is known to have antioxidant properties. It 
is able to scavenge aqueous free radicals [20,4] and to 
regenerate a-tocopherol from the a-tocopheryl radical 
[30,31]. It has been shown that ascorbate can protect 
plasma and LDL lipids from peroxidative damage 
[32,33,4], and it may inhibit the binding of copper ions 
to LDL [7]. 
In the presence of transition metal ions, however, as- 
corbate is well known to sometimes act as a prooxidant 
rather than as an antioxidant, since it can reduce transi- 
tion metal ions. In the presence of hydrogen peroxide 
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this will lead to hydroxyl radical production by the Fen- 
ton reaction [34]: 
e.g. Fe2’ + H202 + Fe3’ + OH’ + OH- 
Hydroxyl radicals have been shown to initiate lipid per- 
oxidation [35]. Thus, in contrast to the above observa- 
tions, one may expect ascorbate to act sometimes as a 
prooxidant [20,7]. Indeed, Hunt et al. [21] have shown 
that ascorbate can both inhibit and promote the forma- 
tion of ceroid (polymerised oxidised lipids) in a model 
system, depending on its concentration. When trace lev- 
els of transition metals are present, low concentrations 
of ascorbate can increase ceroid formation in macro- 
phages [21]. 
The study described here demonstrates that ascorbate 
can either inhibit or promote the modification of LDL. 
Ascorbate was observed to marginally increase the mod- 
ification by macrophages of ‘fresh’ LDL at concentra- 
tions of approximately 40 PM or below, whilst above this 
concentration a strong inhibition of LDL modification 
by macrophages was seen, with total inhibition at be- 
tween 60 PM and 100 ,uM ascorbate (Figs. 1A and 2). 
The mean plasma level of ascorbate in various European 
populations varies between approximately 20 and 55 PM 
WI. 
In contrast, when the same LDL had ‘aged’ for a 
period of at least 10 weeks, ascorbate did not inhibit the 
modification of LDL in the presence of macrophages 
and actually caused a large and dose-dependent modifi- 
cation of LDL in the absence of macrophages (Figs. 1B 
and 2). 
To demonstrate that it was not a change in experimen- 
tal conditions that was causing the observed differences 
in the effects of ascorbate on ‘fresh’ and ‘aged’ LDL of 
the same batch, two batches of LDL of different ages 
were tested in the same experiment (Fig. 2A). As ex- 
pected, ascorbate inhibited the oxidation of the ‘fresh’ 
LDL but modified the ‘aged’ LDL itself. The LDL 
whose oxidation by macrophages was prevented by as- 
corbate when ‘fresh’ (Fig. 2A), showed cell-free modifi- 
cation in the presence of ascorbate after ‘ageing’ 
(Fig. 2B). 
It appears therefore that ascorbate has a modifying 
effect upon LDL that has already undergone some 
change, most probably autoxidation, upon storage. LDL 
is known to autoxidise slowly upon storage [36] and 
LDL stored for long periods has been used as a model 
for mildly oxidised (or minimally modified) LDL [37], 
which has been postulated to be involved in the very 
early stages of atherogenesis [37]. 
There was an increase in TBARS in ‘aged’ LDL incu- 
bated with ascorbate in the absence of cells suggesting 
that the oxidation of the LDL was involved in the mod- 
ification process. In addition, adding the antioxidant 
BHT together with the ascorbate prevented the increase 
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in TBARS and the enhanced uptake of the LDL by the 
target macrophages. It may possibly be of interest that 
ascorbate has been shown to react with lysyl residues 
under autoxidising conditions [38]. 
Previous studies have demonstrated LDL accumula- 
tion in regions of arteries susceptible to the development 
of atherosclerotic lesions and have shown that LDL is 
retained in these regions for longer than in lesion-resis- 
tant sites and that the retention time is increased by 
cholesterol feeding [39]. If some limited degree of oxida- 
tion of LDL were to occur during this time, analogous 
to what happens during storage in a refrigerator over a 
period of months [37], this raises the possibility that 
ascorbate may promote further modification of LDL 
within the arterial wall. 
In summary, ascorbate can either stimulate or inhibit 
LDL modification in vitro depending upon how long the 
LDL has been stored and hence presumably upon its 
‘background’ level of autoxidation. Therefore if mildly 
oxidised LDL were to occur in plasma or in atheroscle- 
rotic lesions, it cannot be automatically assumed that 
ascorbate would act as an antioxidant against its further 
modification. Not all epidemiological studies have 
shown ascorbate to be a protective agent against cardio- 
vascular disease [18,19], and the finding that ascorbate 
can sometimes augment LDL modification in vitro sug- 
gests that further studies should be carried out to ascer- 
tain whether or not ascorbate is truly anti-atherogenic in 
vivo. 
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